GlassScriptPhysician profile
Andrew Michael Joelson
NPI 1770945941
$2,343.21
in general payments reported to CMS, 2019-2025
17 companies · $753 in 2025
The $753 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.91 · 2021: $182 · 2022: $264 · 2023: $431 · 2024: $693 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,877.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $486.95 | 2020-2025 | Epclusa |
| Boston Scientific Corporation | $397.62 | 2022-2023 | Exalt Model D, Axios |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $377.43 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $284.76 | 2023-2025 | |
| Genzyme Corporation | $143.19 | 2024-2025 | |
| Madrigal Pharmaceuticals | $136.36 | 2024 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $133.57 | 2023-2025 | Entyvio, Eohilia |
| Pfizer INC. | $98.21 | 2024-2025 | |
| Celgene Corporation | $58.61 | 2023-2024 | Zeposia |
| Olympus America INC. | $42.28 | 2024-2025 | Single Use Repositionable Clip, Visiglide |
| Aimmune Therapeutics, INC. | $37.33 | 2025 | Vowst |
| Phathom Pharmaceuticals, INC. | $33.66 | 2024 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $30.04 | 2024-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $23.24 | 2025 | |
| Braintree Laboratories, INC. | $21.72 | 2025 | Suflave |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $19.24 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $19.00 | 2025 | Iqirvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Joelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.